It’s a Wrap: Catenion‘s report on ‘Financing Innovation in womens health’ from this year’s FemTechnology Summit in collaboration with Roche.
We’re immensely proud that FEMaLe project adviser Oriana Kraft on behalf of FemTechnology Summit has facilitated this collaborative work together with Dr. Ana Rita da Costa, Pascal Joly, Dr. Ilkin Nehls 👏

According to The Guardian, it’s been 30 years since US Congress ordered the The National Institutes of Health to make sure women were included equally in clinical trials. Despite some progress, research on women still lags, and there’s growing evidence that women and girls are paying the price [1].

The first lady Jill Biden announced a new The White House initiative on women’s health research on 13 November: “To give women and their health care providers the tools and information that they need to more effectively prevent, diagnose, and treat these conditions – from rheumatoid arthritis to menopause to Alzheimer’s disease to cardiovascular disease to endometriosis – our nation must fundamentally change how we approach and fund women’s health research.” [2]

This new report explores the challenges and opportunities in financing innovation in Women’s Health [3]. Despite significant unmet medical needs in female-associated diseases, funding research and development (R&D) in this area have been historically limited. To foster innovation, this report proposes a comprehensive approach, including policy making, public investment, and collaborative efforts, inspired by successful models in other fields, such as orphan drug development.

So, what can we do? This report recommends developing a business case for governmental entities to focus on return on investing in Women’s Health research, breaking silos through a collaborative effort to direct existing and further funding, advocating for regulatory incentives, and engaging in education efforts of regulators.

Read the report here.


[1]: Link

[2]: Link

[3]: Link